Novo Nordisk launches new range of modern insulins
Novo Nordisk, a leading healthcare company in diabetic care has launched modern insulins named NovoMix® 30 Penfill® and NovoRapid® Penfill®, says a press release.
NovoMix® 30 is a pre-mixed dual acting insulin analogue while NovoRapid is a rapid acting insulin analogue. Regarding the advantages of these newly launched insulins Mr Rajan Kumar, Managing Director, Novo Nordisk Pharma (Private) Limited, Bangladesh expressed satisfaction that physicians and patients now have a choice to either go for a durable NovoPen® 3 or a disposable prefilled insulin device.
These penfills are available in global market for more than 7 years and fit into the NovoPen® 3, the world's most widely used durable insulin delivery device offering simplicity, safety and reliability providing accurate dosage of insulin injection.
"These analogue insulins are developed with an objective of overcoming the problems with conventional insulins and are considered more physiological, predictable and safe insulin preparations", says Prof. A K Azad Khan, President, Bangladesh Diabetic Shomiti.
He further reiterated that these analogues offer the following advantages over conventional insulins. It has rapid onset of action, better control of post prandial blood glucose and less risk of major hypoglycaemia and night time hypoglycaemia (low blood sugar). It also offers meal time flexibility as it can be given just before the meals or even after the meals.
For all latest news, follow The Daily Star's Google News channel.
Comments